Harnessing the Therapeutic Potential of Mitochondrial DNA
CohBar is a clinical-stage biotechnology company exploiting the power of the mitochondria and its encoded peptides to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While extensive work has been conducted on the nuclear genome, we are the first to discover potential therapeutics sourced from the mitochondrial genome.
We developed our technology platform to enable us to identify and develop peptides that we believe have promise as potential human therapeutics. One of the key early insights that led to the development of CohBar’s novel platform was the recognition that certain mitochondrially encoded peptides produce effects that are not limited to local regulation within the mitochondria and may have important roles to play in critical systemic biological pathways quite distinct from what has traditionally been thought of as mitochondrial function.
As the first company to mine the mitochondrial genome for therapeutically relevant peptides, we have established a robust IP portfolio.View Pipeline